Aliskiren reduces portal pressure in portal hypertensive rats

European Journal of Clinical Investigation

Volumn 42, Issue 5, 2012, Pages 526-533

  Chang, Ching Chih ^a,b   Lee, Wen Shin ^a,b   Huang, Hui Chun ^a,b   Lee, Fa Yauh ^a,b   Wang, Sun Sang ^a,b   Lin, Han Chieh ^a,b   Nong, Jing Yi ^a   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Aliskiren; Nitric oxide; Portal hypertension; Porto systemic collaterals

Indexed keywords

ALISKIREN; ARGININE; CREATININE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BLOOD FLOW; ARTERY CATHETER; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOPPLER ECHOGRAPHY; DRUG EFFECT; ENZYME INHIBITION; FEMORAL ARTERY; HEART HEMODYNAMICS; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC VEIN; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLANCHNIC BLOOD FLOW; SUPERIOR MESENTERIC ARTERY; TREATMENT DURATION; VASOCONSTRICTION;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COLLATERAL CIRCULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FUMARATES; HYPERTENSION, PORTAL; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PORTAL PRESSURE; PORTAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; RENIN;

EID: 84859706022     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02611.x     Document Type: Article

References (31)

1. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.
2. Westermann D, Schmieder R, Schultheiss HP, Tschope C. Renin inhibitors, clinical experience. J Mol Med 2008;86:691-5.
3. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P et al. A human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76.
4. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008;52:1068-75.
5. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;52:130-6.
6. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008;52:563-72.
7. Brown MJ. Aliskiren. Circulation 2008;118:773-84.
8. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008;93:557-63.
9. Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005;46:1069-76.
10. Danser AH, Batenburg WW, van Esch JH, Krop M. Prorenin anno 2008. J Mol Med 2008;86:655-8.
11. Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 2001;5:629-44.
12. ω-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464-70.
13. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-7.
14. Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001;34:644-50.
15. Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999;30:630-5.
16. Chojkier M, Groszmann RJ. Measurement of the portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371-5.
17. Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane "lung" for small organ perfusions. J Lipid Res 1974;15:182-6.
18. Colombato LA, Sabbà C, Polio J, Groszmann RJ. Influence of anesthesia, postanesthetic state, and restraint on superior mesenteric arterial flow in normal rats. Am J Physiol 1991;260:G1-5.
19. Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the modern management of portal hypertension - primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther 2008;28:178-86.
20. Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986;6:101-6.
21. Lui HF, Stanley AJ, Forrest EH, Jalan R, Hislop WS, Mills PR et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002;123:735-44.
22. Vlachogiannakos J, Tang AK, Patch D, Burroughs AK. Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001;49:303-8.
23. Gonzalez-Abraldes J, Albillos A, Banares R, Del Arbol LR, Moitinho E, Rodriguez C et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-8.
24. Cherney DZ, Lai V, Scholey JW, Miller JA, Zinman B, Reich HN. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010;33:361-5.
25. Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-Lopez F, Rodes J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981;11:221-9.
26. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121:389-95.
27. Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M et al. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest 2003;33:1006-12.
28. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23:417-26.
29. Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009;54:633-8.
30. Ke CY, Lee CC, Lee CJ, Subeq YM, Lee RP, Hsu BG. Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats. Eur J Clin Invest 2010;40:301-9.
31. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410.